AVGO
Broadcom Inc.
AVGO has the edge over LLY overall, supported by stronger modeled upside and stronger fundamentals.
LLY
Eli Lilly and Company
LLY has slightly lower modeled downside risk, despite its lower overall score.
AVGO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AVGO's revenue, profitability, cash flow and balance sheet are all currently strong.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AVGO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $364 | — |
| Cheap | 27x | $211 | -42% |
| Current | 46x | $364 | — |
| Fair | 49x | $384 | +5.3% |
| Expensive | 86x | $671 | +84% |
Historical ranges are pointers, not guarantees.
AVGO has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AVGO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for AVGO, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AVGO on the outlook, with more favorable profitability expectations.
AVGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.23 | +145% |
| Q3 2026 | $7.84 | +100% |
| Q2 2026 | $6.01 | +125% |
| Q1 2026 | $5.13 | +145% |
| Q4 2025 | $4.77 | +288% |
| Q3 2025 | $3.92 | +241% |
| Q2 2025 | $2.67 | +15% |
| Q1 2025 | $2.09 | -23% |
| Q4 2024 | $1.23 | -63% |
AVGO earned $7.84 per share over the past year, up 100% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
AVGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $29.6B | +86% |
| Q2 2026 | $22.2B | +48% |
| Q1 2026 | $19.3B | +29% |
| Q4 2025 | $18B | +28% |
| Q3 2025 | $16B | +22% |
| Q2 2025 | $15B | +20% |
| Q1 2025 | $14.9B | +25% |
| Q4 2024 | $14.1B | +51% |
AVGO's revenue has grown year over year every quarter since late 2020: $29.6B last quarter, up 86% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 54% | +17 points |
| Q2 2026 | 49% | +9.8 points |
| Q1 2026 | 44% | +2.4 points |
| Q4 2025 | 42% | +8.8 points |
| Q3 2025 | 37% | +7.9 points |
| Q2 2025 | 39% | +15 points |
| Q1 2025 | 42% | +25 points |
| Q4 2024 | 33% | -13 points |
AVGO has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AVGO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
AVGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $13.7B | +95% |
| Q2 2026 | $10.3B | +60% |
| Q1 2026 | $8B | +33% |
| Q4 2025 | $7.5B | +36% |
| Q3 2025 | $7B | +47% |
| Q2 2025 | $6.4B | +44% |
| Q1 2025 | $6B | +28% |
| Q4 2024 | $5.5B | +16% |
AVGO has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
AVGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +11M shares |
| 1 year | +0.6% | +27M shares |
| 3 years | +14% | +617M shares |
| 5 years | +14% | +597M shares |
| Available history | +17% | +697M shares |
AVGO has 4.9B diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $600M |
| Q1 2026 | $7.9B |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | — |
| Q4 2024 | — |
AVGO spent $8.4B buying back its own shares over the past year, about three times what it spent the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AVGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AVGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.3x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 4.1x | High |
AVGO has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AVGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 20.3 | Neutral |
AVGO's weekly RSI is 51 (neutral) and its Stochastic is 20 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AVGO PE vs Technology Sector
| Metric | AVGO | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 28x | 67% above |
| PE % | 47 | 35 | 12 pts above |
AVGO has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AVGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $338.0 | 7.8% above |
| 20 week MA | $362.1 | 0.6% above |
| 50 week MA | $363.0 | 0.4% above |
| 100 week MA | $313.8 | 16% above |
| 200 week MA | $214.3 | 70% above |
AVGO is in an uptrend: it's above all five of its weekly moving averages, and 70% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
AVGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $31.7 | $43.2 | +36% |
| 2021 | $43.2 | $66.5 | +54% |
| 2022 | $66.5 | $55.2 | -17% |
| 2023 | $55.2 | $111.6 | +102% |
| 2024 | $111.6 | $241.8 | +117% |
| 2025 | $241.8 | $352.1 | +46% |
| 2026 YTD | $352.1 | $364.4 | +3.5% |
AVGO has finished higher in five of the last six years, three of them by more than 50%. It's up 3.5% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AVGO on returns for 2026, with the stronger performance.